Q3: Chen Is Still Bullish on This Precious Metal
Source: Streetwise Reports  (6/29/23)
Asset manager Chen Lin continues to rely heavily on this precious metal. Find out his top picks for the third quarter of 2023. More >

Telehealth Co. Expands to More Patients, Picks Up Coverage
Source: Streetwise Reports  (6/26/23)
Reliq Health Technologies Inc. continues to pick up more contracts with skilled nursing facilities (SNFs) and other health care groups. Now it also has gotten analyst attention. More >

New Drug for Bone Growth Disorder Improves Height Velocity
Source: Dr. Thomas Shrader  (6/21/23)
Phase 2 trial data at six months are positive in children with achondroplasia, noted a BTIG report. More >

Biotech Co. Completes Step Toward Psychedelic Treatment for Brain Injuries
Source: Streetwise Reports  (6/16/23)
Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream. More >

777% Gain Implied in Analyst's Target Price on Biopharma Co.
Source: Dr. Yi Chen  (6/14/23)
Results from a Phase 2 trial of this U.S. company's cystic fibrosis drug are due out next month, noted an H.C. Wainwright & Co. report. More >

Telehealth Co. Expands With Six New Contracts in Three States
Source: Streetwise Reports  (6/13/23)
New contracts are expected to add more than 3,000 new patients to Reliq Health Technologies Inc.'s platform by the first quarter of next year, the company said. More >

Court Grants Firm Protection From Creditors
Source: Andrew Semple  (6/12/23)
Despite this development, there are still some ways this Canadian retailer-distributor could salvage some value for shareholders, noted an Echelon Capital Markets report. More >

Biotech Co. To Exit Health Care Services
Source: Streetwise Reports  (6/12/23)
Friday, Awakn Life Sciences Corp. announced it would be taking focus away from healthcare services and instead concentrate its efforts exclusively on research and development for therapeutics for addiction treatment. Read more to learn what the global addiction treatment market looks like and where the company is headed in the future. More >

Key Catalyst for US Biopharma Stock on Track for Q4/23
Source: Ed Arce  (6/9/23)
Readout of a Phase 2b trial is expected then, and positive data could support approval of the company's drug candidate, noted an H.C. Wainwright & Co. report. More >

Medical Device Co. Completes Merger in Q1/23
Source: Jeffrey Cohen  (6/8/23)
Due to the acquisition, the U.S.-based firm generated 844% more revenue during the quarter than it did a year earlier, noted a Ladenburg Thalmann report. More >

Healthcare Tech Firm Grows Revenue 10% YOY in Q1/23
Source: Rob Goff  (6/5/23)
This positive start to 2023 bodes well for the company turning EBITDA positive later this year, which is expected, noted an Echelon Capital Markets report. More >

FDA Approval, Private Placement Funding Buoy Biotech Firm
Source: Streetwise Reports  (6/5/23)
Krystal Biotech Inc. appears to be picking up steam for the year's second half. The company's Vyjuvek topical gel for treating Dystrophic Epidermolysis Bullosa (DEB) was approved by the FDA on May 19, leading to a major funding announcement. More >

Telehealth Co. Notches First Profitable Quarter
Source: Streetwise Reports  (6/2/23)
Reliq Health Technologies announces record revenues for the three months ending March 31 and its first profitable quarter after a loss during the same quarter in 2022. More >

Analyst Says Pharma Co. 'Meaningfully Undervalued'
Source: Stefan Quennevill  (6/1/23)
"We continue to view Mindset as meaningfully undervalued," Stefan Quennevill reported in an Echelon Capital Markets research note. More >

U.S. Firm's Earnings To Remain Robust Through 2023
Source: Andrew Semple   (5/25/23)
Recent and upcoming events, including new store openings, will drive sales and revenue growth for this retailer and wholesaler, noted an Echelon Capital Markets report. More >

Animal Feed Company Evaluating Strategic Alternatives
Source: Streetwise Reports  (5/23/23)
Avivagen is considering strategic plans to maximize value to shareholders. Read more to see what the possibilities may be for shareholder profit. More >

Wellness Co.'s Q1/23 Results Better Than Expected
Source: Andrew Semple  (5/19/23)
Results for the first quarter of this year for Ayr Wellness Inc. were better than expected, reported an Echelon Capital Markets research note. More >

Telehealth Co. Signs Contract With US Health Plan Serving 1 Million Patients
Source: Streetwise Reports  (5/18/23)
Telehealth company Reliq Health Technologies signs a contract with a U.S. health plan that operates in five states with over 3,000 doctors and more than 1 million patients. More >

Biopharma Co. Ceases Program to Optimize Resources
Source: Hartaj Singh  (5/16/23)
This French developer of investigative cancer therapies is focused on advanced its remaining programs and is amply funded to do so, noted an Oppenheimer report. More >

Digital Health Co. Grows Revenue and Reduces Expenses
Source: Rob Goff   (5/10/23)
This Canadian healthcare tech company is showing projected returns of over 241% for investors, noted an Echelon Capital Markets research note. More >

Telehealth Co. Expands into Arkansas
Source: Streetwise Reports  (5/5/23)
Telehealth company Reliq Health Technologies signs five new contracts in four states for its iUGO platform, including its first contract in the state of Arkansas, where chronic diseases cost billions annually. More >

Pharmaceutical Company Sets Gold Standard for New Drugs
Source: Streetwise Reports  (4/26/23)
Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history. More >

Adding Silver a Solid Move
Source: Michael Ballanger  (4/24/23)
Michael Ballanger of GGM Advisory Inc. reviews the state of the SPX Index, the gold-to-silver ratio, and the current lithium market. More >

As Countries Bolster Defense, Opportunities Emerge
Source: Streetwise Reports  (4/21/23)
Defense stocks are uniquely positioned to enjoy considerable, reliable funding from government contracts. This stability, and the ensuing profitability, increases during times of international political instability. More >

Biotech Co. Secures Majority UK Gov Funding for Phase 3 Trial
Source: Streetwise Reports  (4/19/23)
Phase 3 trials are the last major step in new drug approval and can cost a lot to operate. However, one Canadian pharma company's product is so promising it has convinced the UK government to foot most of the bill. More >